Drug Delivery Partnering Yearbook 2013 -



Published: January 2013 Pags: 200+


The Drug Delivery Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012.


Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.


The initial chapters of this report provide an orientation of 2012’s dealmaking and business activities.


Chapter 1 provides an overview of the trends in dealmaking during 2012 covering trends by deal type, stage of development, technology type and therapeutic indication.


Chapter 2 provides a review of the leading deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Chapter 4 provides a comprehensive directory of all partnering deals announced during 2012. 


The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012. 


Key benefits


Drug Delivery Partnering Yearbook 2013 series provides the reader with the following key benefits:


  • In-depth understanding of recent dealmaking trends during 2012     
  • Comprehensive access to all  deals entered into by the world’s biopharma companies during 2012
  • Detailed access to actual partnership deals and contracts entered into by the leading fifty bigpharma companies
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Drug Delivery Partnering Yearbook 2013 series is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.


Drug Delivery Partnering Yearbook 2013 includes:


  • Trends in dealmaking in the biopharma industry during 2012
  • Comprehensive directory of partnering deals in 2012
  • Links to online access to all deals and alliances
  • The leading partnering deals by value in 2012
  • Most active partnering dealmakers during 2012


In Drug Delivery Partnering Yearbook 2012 series the partnering and M&A deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy area
  • Technology type


Each deal title links via Weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand. 

Executive Summary 


Chapter 1 – Trends in dealmaking during 2012 


1.1. Bigpharma dealmaking activity

1.2. Partnering by deal type

1.3. Partnering by industry sector

1.4. Partnering by stage of development

1.5. Partnering by technology type

1.6. Partnering by therapy area


Chapter 2 – Leading deals during 2012 


2.1. Introduction

2.2. Top deals by value during 2012


Chapter 3 – Bigpharma deals during 2012 


3.1. Introduction

3.2. How to use bigpharma partnering deals

3.3. Bigpharma partnering company profiles for 2012






Aspen Pharmacare



Baxter International


Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb



Daiichi Sankyo

Dainippon Sumitomo


Eli Lilly

Endo Pharmaceuticals 

Forest Laboratories


Gilead Sciences           




Johnson & Johnson

Kyowa Hakko Kirin



Merck & Co

Merck KGaA

Mitsubishi Tanabe


Novo Nordisk












Warner Chilcott



Chapter 4 – Partnering deals directory 2012 


4.1. Introduction           

4.2. Company A-Z        

4.3. By deal type

4.4. By stage of development

4.5. By technology type

4.6. By therapy area


About Wildwood Ventures      


Current Partnering       

Current Agreements

Current Reports

Recent titles from CurrentPartnering

Order Form – Reports


Table of figures 


Figure 1: Bigpharma – top 50 – January to December 2012

Figure 2: Bigpharma deal frequency – 2012

Figure 3: Partnering by deal type during 2012

Figure 4: Partnering by industry sector during 2012

Figure 5: Partnering by stage of development during 2012

Figure 6: Partnering by technology type during 2012

Figure 7: Partnering by therapy area during 2012

Figure 8: Top deals by value during 2012